Facit-backed oncological development initiative Triphase Accelerator has struck a deal with Celgene for its TRPH-395 blood cancer treatment as the drug nears clinical trials

Triphase Accelerator, a Canada-based oncological treatment accelerator backed by commercialisation agency Fight Against Cancer Innovation Trust (Facit), is to receive $40m upfront under a business development pact with drug maker Celgene.
Facit provides funding to advance local oncological projects including spinouts and is allied to the Ontario Institute for Cancer Research.
Under the partnership, Triphase Accelerator will fund proof-of-concept clinical trials of its precision TRPH-395 therapy in blood cancer indications, which recognises specific DNA hallmarks of blood cancer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?